To re-rate, Sanofi needs to show tangible progress - RBC starts at 'sector perform'

Sanofi SA

09/09/2026 08:28

** RBC starts Sanofi SASY.PA at "sector perform", seeing the French pharmaceutical firm as a "show-me" story requiring tangible progress before a positive re-rating
     ** Expectations of over €10 billion ($11.64 billion) in key product sales by 2030 are already priced in, RBC says, while recent drug launches will take time to realize full potential
** Patent cliff for eczema drug Dupixent is approaching despite the drug's strength, but RBC sees strong probability of extending exclusivity until at least 2033
** Sanofi trades at a steep discount, the broker says; sets PT at €80
** Out of 27 analysts covering Sanofi, 14 rate it "strong buy" or "buy,"​ 12 "hold" and one "sell"  —  LSEG data
($1 = 0.8591 euros)

(Reporting by Dimitri Rhodes in Gdansk)
((dimitri.rhodes@thomsonreuters.com))